Table 4.

Regression analysis for prognostic risk factors of APA-GI.

Variable	Single factor		Multiple factors
	HR(95%CI)	P–value	HR(95%CI)	P-value
Age, y		0.078		0.913
<60	1		1
≥60	1.40 (0.96–2.05)		1.05 (0.42–2.62)
Sex		0.075		0.551
Male	1		1
Female	0.70 (0.47–1.04)		1.38 (0.48–3.94)
AFP, ng/ml		0.005		0.877
<200	1		1
≥200	1.67 (1.17–2.38)		0.93 (0.38–2.27)
Primary site		0.241
Stomach	1
Large intestine	0.57 (0.32–1.02)
Small intestine	0.66 (0.16–2.66)
Esophagus	1.04 (0.14–7.45)
Multiple primary sites	0.26 (0.04–1.86)
Tumor size, cm		0.028		0.59
<5	1		1
≥5	1.99 (1.08–3.65)		0.79 (0.34–1.83)
Pathological type		0.660
Adenocarcinoma	1
Signet ring cell carcinoma	0.78 (0.44–1.37)
Mucinous adenocarcinoma	0.88 (0.45–1.75)
Differentiation		0.926
Highly differentiated	1
Moderately differentiated	0.90 (0.21–3.79)
Poorly differentiated	0.84 (0.20–3.42)
pT		0.056		0.96
1	1		1
2	1.60 (0.32–7.98)		1.52 (0.15–15.72)
3	2.68 (0.49–14.73)		1.95 (0.18–21.38)
4	3.98 (0.96–16.50)		1.60 (0.18–14.01)
pN		0.028		0.071
0	1		1
1	2.54 (0.99–6.57)		2.80 (0.79–9.90)
2+3	2.68 (1.29–5.56)		3.05 (1.16–8.06)
TNM staging		<0.001		0.486
I-III	1		1
IV	3.99 (2.69–5.90)		1.39 (0.55-3.53)
Extrahepatic metastasis		0.031		0.127
No	1		1
Yes	1.50 (1.04–2.16)		1.95 (0.83–4.60)
Hepatic metastasis		<0.001		0.015
No	1		1
Yes	2.79 (1.91–4.06)		3.59 (1.28–10.02)
Lymphatic or/and blood vessel invasion		0.009		0.140
No	1		1
Yes	2.30 (1.24–4.29)		2.04 (0.79–5.27)
Nerve invasion		0.064		0.884
No	1		1
Yes	1.76 (0.97–3.21)		0.92 (0.29–2.92)
Hepatoid Adenocarcinoma#		0.102		0.228
No	1
Yes	1.68 (0.90–3.12)
AFP IHC		0.375		0.288
Low expression	1
High expression	1.35 (0.70–2.62)

^#73 surgical patients out of 100 patients receiving second pathological diagnosis were included.